- Assistant Professor, RI-INBRE Faculty Scholar
- Office: 395N Lab: 450
- Email: Kaitlin.dailey@uri.edu
- Office Location: Office location: Avedisian Hall, 7 Greenhouse Road, Kingston, RI 02881
- Website
- Accepting Students: Yes
Research
The Dailey Lab’s current efforts characterize the live biologic Clostridium novyi-NonToxic (C. novyi-NT) as an intravenously delivered pancreatic cancer therapeutic able to target both primary and metastatic tumors. Dr. Dailey developed a first-of-its-kind synthetic/engineering biology platform for targeted gene editing using CRISPR/Cas9n in C. novyi-NT. We use this technology to harness the natural characteristics of weakened C. novyi-NT. Engineered C. novyi-NT has the potential for efficacy against a broad spectrum of solid tumors – as well as health applications during long duration space travel. Such space health applications include generating energy as microbial fuel cells and on-demand pharmaceutical secretion to replace required medicinal payloads. Join us in these efforts – we have openings at all levels!
Education
Postdoctoral Research Associate, Microbiology, Cancer Biology, Cancer Immunology.
Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
Ph.D., Cell and Molecular Biology, Genetic Engineering, Pharmaceutical Sciences, North Dakota State University, Fargo, ND
B.S., Biology, North Park University, Chicago, IL
Selected Publications
Engineering Biology Research Consortium (2024). Engineering Biology for Space Health: An Innovative Research Roadmap. Retrieved from http://roadmap.ebrc.org. doi: 10.25498/E4D59R. Invited author. Publication was peer reviewed continuously as written by EBRC members.
Dailey, K. M*.; Small, J.M.; Pullan, J.E.; Winfree, S.; Vance, K.; Orr, M.; Mallik, S.; Bayles, K.W.; Hollingsworth, M.A.; Brooks, A. E. An Intravenous Pancreatic Cancer Therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-NT. (2023) PLoS One. 2023, 18(11): e0289183; https://doi.org/10.1371/journal.pone.0289183
Roe, J.M.; Seeley, K.; Bussard, C.J.; Eischen Martin, E.; Mouw, E.G.; Bayles, K.W.; Hollingsworth, M.A.; Brooks, A.E.; and Dailey, K.M.* (2023) Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria. Pharmaceutics 2023(15), 2004 https://doi.org/10.3390/pharmaceutics15072004
Pullan, J.E., Dailey K.M., Bhallamudi S., Feng L., Alhalhooly L., Froberg J., Molden T., Venkatachalem S., Choi Y., Brooks A.E., Mallik S.* (2022) Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple Negative Breast Cancer. ACS Ap. Bio. Mat.
Pierce, K.; Miklavcic, W.R.; Cook, K.; Switzer, M.; Bayles, K.W.; Hollingsworth, M.A.; Brooks, A.E.; Pullan, J.E.; Dailey, K.M.* (2021) The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors Nanomaterials, 2021(11), 301
Dailey, K. M.*; Allgood, J. E; Johnson, P. R., Ostelie, M. A.; Schaner, K. C.; Brooks, B. D.; Brooks, A.E. (2021) The Next Frontier of Pharmaceutical Science: Accomplishing Clinical Translation of Oncolytic Bacteria through Genetic Modification. Future Microbiology 16:341-368.
Dailey, K. M.*; Jacobson, R.I.; Johnson, P. R.; Woolery, T. J.; Kim, J.; Jansen, R.; Mallik, S.; Brooks, A.E. (2021) Methods and Techniques to Accomplish the Development of Clostridium novyi-NT as an Oncolytic Bacteria. Frontiers in Microbiology 2021;12:624618.
Dailey, K.M.*; Jacobson, R.I.; Kim, J.; Mallik, S.; Brooks, A.E. (2021) Efficacy of C. novyi against a Panel Pancreatic Cancer Cells. Biomedical Science Instrumentation. 57 (492)
Shreffler, J. W.; Pullan, J. E.; Dailey, K. M.; Mallik, S.; Brooks, A. E.* (2019) Overcoming Hurdles in Nanoparticle Clinical Translation: The Influence of Experimental Design and Surface Modification. Int. Journal of Molecular Science 20 (23)